<DOC>
	<DOCNO>NCT00448240</DOCNO>
	<brief_summary>The purpose study determine combination Erlotinib , Cisplatin/Carboplatin , Paclitaxel effective first line treatment metastatic , recurrent persistent squamous cell carcinoma head neck .</brief_summary>
	<brief_title>Erlotinib ( Tarceva ) During First Line Standard Platinum Containing Chemo Advanced Squamous Cell Head Neck Cancer</brief_title>
	<detailed_description>We hypothesize Erlotinib fail enhance effect chemotherapy response survival Erlotinib 's cytostatic effect , result slow cell cycle , turn result hamper cytotoxic effect chemotherapy lead lack synergism combination . We propose sequential approach combination allow drug use optimum time , sequence Erlotinib , give 24 hour chemotherapy allow chemotherapy exert effect cell actively cell cycle , deliver Erlotinib time cell try return cell cycle hence slow growth rate tumor cell population . By withdraw Erlotinib 4 day prior next chemotherapy cycle , allow cell go back cell cycle therefore become susceptible chemotherapy . Patients treat intravenous paclitaxel 3 hour follow intravenous cisplatin/carboplatin Day 1 21 day cycle . Patients treat Erlotinib load dose 300mg Day 2 follow 150 mg orally daily Days 3-17 cycle paclitaxel cisplatin/carboplatin . The primary objective study assess response rate combination erlotinib , cisplatin/carboplatin paclitaxel first line treatment set metastatic , recurrent persistent squamous cell carcinoma head neck . Secondary objective assess toxicity , median survival , progression free survival .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Squamous cell carcinoma head neck region metastatic , recurrent persistent surgery and/or radiation No prior chemotherapy metastatic , recurrent persistent disease Not 1 prior adjuvant neoadjuvant chemotherapy regimen allow Chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>